KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $6.3 billion.

  • Vertex Pharmaceuticals' Cash & Current Investments fell 3.64% to $6.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 billion, marking a year-over-year decrease of 25.88%. This contributed to the annual value of $6.1 billion for FY2024, which is 45.48% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Cash & Current Investments is $6.3 billion, which was down 1.50% from $6.4 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cash & Current Investments registered a high of $11.9 billion during Q3 2023, and its lowest value of $5.8 billion during Q2 2024.
  • Its 3-year average for Cash & Current Investments is $8.4 billion, with a median of $6.5 billion in 2024.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cash & Current Investments surged by 65.23% in 2021 and then tumbled by 48.42% in 2024.
  • Vertex Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $7.5 billion in 2021, then spiked by 43.24% to $10.8 billion in 2022, then increased by 4.08% to $11.2 billion in 2023, then tumbled by 45.48% to $6.1 billion in 2024, then declined by 3.64% to $6.3 billion in 2025.
  • Its Cash & Current Investments stands at $6.3 billion for Q3 2025, versus $6.4 billion for Q2 2025 and $6.2 billion for Q1 2025.